Human medicines European public assessment report (EPAR): Riximyo, rituximab, Lymphoma, Non-Hodgkin;Arthritis, Rheumatoid;Microscopic Polyangiitis;Wegener Granulomatosis, Date of authorisation: 15/06/2017, Revision: 14, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.